SUMMARY
Introduction: In this study, the effectiveness and safety of topiramate treatment in children with chronic daily headache were investigated.
Materials and Method: This study was perfomed prospectively among 100 children who were diagnosed with chronic daily headache. Before the treatment, Pediatric Migraine Disability Assesment (PEDMİDAS) scores and grades of the patients were determined. Topiramate was given as 1 mg/kg/day then the dose was increased to 2 mg/kg/day at the tenth day of the treatment. At the third month, PEDMİDAS scores and grades were redetermined and compared with the first one.
Results: The PEDMİDAS scores of the patients before and after the treatment were found as 34.60±22.28, 12.77±12.2, respectively. There was a statistical difference between these two values (p<0.001). When we group the patients according to the PEDMİDAS scores before the treatment 68% of the patients were grouped as grade 4, 23% as grade 3, 6% as grade 2 and 3% as grade 1; then after the treatment these percentages changed as 38.4% for grade 4, 29.4% for grade 3, 21.5% for grade 2 and 10.7% for grade1, respectively. Also forgetfulness in 8.8% (n=6) of patients, weight loss (average 250 grams) in 5.8% (n=4) and paresthesia in 4.4% (n=3) were determined.
Conclusions: This study has shown that topiramate is safe, well tolerable and can be used with low doses in the treatment of chronic daily headache in childhood and is an alternative treatment choice that can be used in case no answers with other drugs. (Journal of Current Pediatrics 2010; 8: 20-3)
Key words: Topiramate, efficacy, reliability, childhood, headache

SUMMARY
Introduction: In this study, the effectiveness and safety of topiramate treatment in children with chronic daily headache were investigated.
Materials and Method: This study was perfomed prospectively among 100 children who were diagnosed with chronic daily headache. Before the treatment, Pediatric Migraine Disability Assesment (PEDMİDAS) scores and grades of the patients were determined. Topiramate was given as 1 mg/kg/day then the dose was increased to 2 mg/kg/day at the tenth day of the treatment. At the third month, PEDMİDAS scores and grades were redetermined and compared with the first one.
Results: The PEDMİDAS scores of the patients before and after the treatment were found as 34.60±22.28, 12.77±12.2, respectively. There was a statistical difference between these two values (p<0.001). When we group the patients according to the PEDMİDAS scores before the treatment 68% of the patients were grouped as grade 4, 23% as grade 3, 6% as grade 2 and 3% as grade 1; then after the treatment these percentages changed as 38.4% for grade 4, 29.4% for grade 3, 21.5% for grade 2 and 10.7% for grade1, respectively. Also forgetfulness in 8.8% (n=6) of patients, weight loss (average 250 grams) in 5.8% (n=4) and paresthesia in 4.4% (n=3) were determined.
Conclusions: This study has shown that topiramate is safe, well tolerable and can be used with low doses in the treatment of chronic daily headache in childhood and is an alternative treatment choice that can be used in case no answers with other drugs. (Journal of Current Pediatrics 2010; 8: 20-3)
Key words: Topiramate, efficacy, reliability, childhood, headache

Article in Turkish
(Use the link for full-text in Turkish)